Acadia Pharmaceuticals (ACAD) said in a late Wednesday filing that Chief Operating Officer Brendan Teehan will be involuntarily terminated without cause, effective immediately.
Chief Executive Catherine Adams will assume responsibilities of the COO role until a successor is appointed, the company said.
Teehan will remain with the company as a non-executive employee until Dec. 31, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments